04 July 2012
Vol 4, Issue 141
  • Contents

    • Commentary

    • Perspective

      • Circulating Tumor Cells: Getting More from Less

        Continued technologic innovation may soon permit the interrogation of rare circulating tumor cells to understand tumor biology, guide drug development, and personalize treatment for cancer patients.

    • Research Articles

      • Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease

        Neural cells derived from induced pluripotent stem cells from patients with genetic forms of Parkinson’s disease provide insights into disease pathogenesis.

      • Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

        ALK inhibitors induce complete tumor regression in a mouse model of ALK-driven neuroblastoma.

      • A Tissue Engineering Solution for Segmental Defect Regeneration in Load-Bearing Long Bones

        A polycaprolactone-tricalcium phosphate scaffold with recombinant human BMP-7 heals critical-sized bone defects in sheep.

    • Editors' Choice

      • Antibodies Stop Secretion of Antibodies in Lupus

        Serum from patients with lupus induces development of dendritic cells that promote B cell responses, including autoantibody secretion.

      • You Are What and When You Eat

        Time-restricted feeding without reducing caloric intake prevents metabolic disease in mice fed a high-fat diet.

      • The Big Picture

        A new method helps to discover new genes that affect brain integrity.

      • Microbiota and Immune Cells: Friends with Benefits

        Host-microbial mutualism between gut immune cells and species-specific microbes has developed in mammals and is essential for normal gut immunity.

About The Cover

Cover image expansion

ONLINE COVER Flagging Down Tumor Cells. Cancer cells present in your bloodstream could indicate tumor metastasis to other sites in the body. To detect these rare, circulating tumor cells (CTCs), Issadore and colleagues attached magnetic nanoparticles to CTCs found in the blood of ovarian cancer patients. These cells were then flowed through a magnetic microdevice where they acquired a magnetic moment, as is colorfully depicted on this week's cover. The magnetic fields of the patients' CTCs were then identified and quantified. The hope is to eventually deploy this microdevice to the clinic, where CTC burden could correlate with cancer progression. See the related Perspective by Lang. [CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE]